Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02144701 · ClinicalTrials.gov registry record · NA
Lactobacillus Rhamnosus GG in Reducing Incidence of Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
A NA study, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT02144701 is a NA study that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 33 participants.
The verdict
NCT02144701, a NA study, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
This randomized pilot clinical trial studies Lactobacillus rhamnosus GG in reducing incidence of graft-versus-host disease in patients who have undergone donor stem cell transplant. Lactobacillus rhamnosus GG may be effective at preventing for graft-versus-host disease caused by a donor stem cell transplant.
Interventions
- DIETARY_SUPPLEMENT Lactobacillus rhamnosus GG
- OTHER laboratory biomarker analysis was not performed because of no differences in the clinical outcomes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2013-02-18 |
| Est. Completion | 2018-02-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02144701
The ClinicalTrials.gov registry entry for NCT02144701 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lactobacillus rhamnosus GG is the first listed.
NCT02144701 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02144701 about?
NCT02144701 is a clinical study titled "Lactobacillus Rhamnosus GG in Reducing Incidence of Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant". This randomized pilot clinical trial studies Lactobacillus rhamnosus GG in reducing incidence of graft-versus-host disease in patients who have undergone donor stem cell transplant. Lactobacillus rhamnosus GG may be effective at preventing for graft-versus-host disease caused by a donor stem cell tr...
What is the current status of trial NCT02144701?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2013-02-18. Estimated completion is 2018-02-28.
What interventions are being tested in trial NCT02144701?
The interventions under investigation include: Lactobacillus rhamnosus GG (DIETARY_SUPPLEMENT), laboratory biomarker analysis was not performed because of no differences in the clinical outcomes (OTHER).
Who is sponsoring clinical trial NCT02144701?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.